Cefuroxime Axetil 500 mg + Potassium Clavulanate 125 mg Tablets – ERINIAS®-CV
Antibiotic product profile for pharmaceutical trade and business enquiries
QUICK FACTS
- Composition: Cefuroxime axetil 500 mg + potassium clavulanate 125 mg
- Dosage Form: Tablet
- Therapeutic Category: Antibiotic
- Brand: ERINIAS®-CV
- Manufacturing: WHO-GMP certified manufacturing facility
- Business Availability: Available for authorised pharmaceutical trade partners
- Franchise Fee: Zero
- Prescription Status: Schedule H medicine
Cefuroxime Axetil 500 mg + Potassium Clavulanate 125 mg Tablets
Cefuroxime axetil 500 mg + potassium clavulanate 125 mg gives ERINIAS-CV a defined place within the ERINIAS antibiotic range.
The combination extends the existing cefuroxime portfolio beyond standalone 250 mg and 500 mg strengths. That gives field teams a broader brand conversation without introducing an unrelated identity.
ERINIAS-CV Product Specifications
- Brand: ERINIAS®-CV
- Composition: Cefuroxime axetil 500 mg + potassium clavulanate 125 mg
- Dosage Form: Tablet
- Category: Cephalosporin antibiotic with beta-lactamase inhibitor
- Marketing Company: Eridanus Healthcare
- Manufacturing: Manufactured at a WHO-GMP certified facility
- Prescription Status: Schedule H
- Business Availability: Available to eligible distributors, stockists and institutional buyers
- Storage: As directed on the approved product label
Cefuroxime Axetil and Potassium Clavulanate Composition
Cefuroxime axetil 500 mg — A second-generation cephalosporin. It acts by interfering with bacterial cell-wall synthesis.
Potassium clavulanate 125 mg — A beta-lactamase inhibitor. It helps protect susceptible beta-lactam antibiotics from certain bacterial enzymes.
Why ERINIAS-CV Adds Value to an Antibiotic Portfolio
ERINIAS-CV is not an isolated cefuroxime brand within the Eridanus portfolio. It sits beside ERINIAS 250 and ERINIAS 500.
That matters commercially. A representative already discussing the ERINIAS range can cover standalone cefuroxime and the cefuroxime-clavulanate combination within one brand family. This keeps product recall and portfolio presentation simpler during repeat field calls.
ERINIAS Cefuroxime Range
- ERINIAS® 250 — Cefuroxime axetil 250 mg
- ERINIAS® 500 — Cefuroxime axetil 500 mg
- ERINIAS®-CV — Cefuroxime axetil 500 mg + potassium clavulanate 125 mg
The three presentations create a more complete cefuroxime-focused range for the trade partner. Selection between these products remains a prescribing decision based on clinical need.
Clinical Applications of Cefuroxime Clavulanate
ERINIAS-CV is intended for prescription use in susceptible bacterial infections where this combination is clinically appropriate.
- Upper respiratory tract infections
- Lower respiratory tract infections
- Urinary tract infections
- Gonococcal urethritis
- Other susceptible bacterial infections where the combination is clinically appropriate
Use should follow the prescribing physician’s assessment and local antimicrobial guidance.
Target Prescriber Base
ERINIAS-CV gives field teams relevant call points across commonly covered antibiotic specialties.
- General Physicians
- Internal Medicine specialists
- ENT specialists
- Pulmonologists
- Urologists
- Hospital and institutional prescribers
This makes the product relevant for teams already working across general medicine and antibiotic segments.
Key Safety Points for Field Detailing
- ERINIAS-CV is a prescription antibiotic and should only be promoted for appropriate bacterial infections.
- A history of serious cephalosporin or other beta-lactam hypersensitivity requires clinical attention.
- Antibiotic-associated diarrhoea can occur. Severe or persistent diarrhoea requires medical evaluation.
- Field communication should support responsible antibiotic use and antimicrobial stewardship.
- The product should not be positioned for viral illnesses or unnecessary antibiotic use.
- Schedule H retail sale requires the prescription of a Registered Medical Practitioner.
A Practical Business Opportunity for Distributors
- ERINIAS-CV can complement an existing antibiotic portfolio without requiring an entirely new prescriber base.
- Territory opportunities are considered according to area availability.
- Approved monopoly arrangements are documented through commercial terms.
- Verified orders are processed within 24 hours.
- Ongoing coordination is handled through a dedicated relationship manager.
For Stockists and Institutional Buyers
- ERINIAS-CV is available for authorised pharmaceutical trade requirements.
- Bulk requirements can be planned against current inventory.
- Repeat supply can be coordinated with the Eridanus Healthcare team.
- GST-compliant billing is provided for eligible trade transactions.
- Supply remains subject to stock and logistics availability.
For Medical Representatives Exploring Their Own Business
- ERINIAS-CV can suit representatives who already work with antibiotic prescribers.
- Existing relationships with physicians, ENT specialists and medicine practitioners can support territory development.
- The wider ERINIAS cefuroxime range gives representatives more than one presentation to discuss during a call.
- Commercial onboarding remains subject to Drug Licence, GST and territory verification.
Why Work With Eridanus Healthcare
- WHO-GMP certified manufacturing facility for ERINIAS-CV
- 400+ pharmaceutical products across multiple therapy areas
- Contractually defined monopoly arrangements for approved territories
- Zero franchise fee
- Zero renewal charge
- Verified order processing within 24 hours
- Product and promotional material support
- Dedicated relationship manager
- Access to multiple strengths within established brand families
Antibiotic PCD Pharma Franchise Availability
ERINIAS-CV is open for business enquiries from eligible pharmaceutical professionals across available territories in India.
The opportunity suits distributors, stockists and experienced field professionals looking to expand an antibiotic portfolio. Territory allocation depends on current availability.
Drug Licence and GST verification are required before commercial activation.
Frequently Asked Questions
Is cefuroxime axetil 500 mg + potassium clavulanate 125 mg available from Eridanus Healthcare?
Yes. The combination is marketed as ERINIAS®-CV and is available for authorised pharmaceutical trade enquiries.
What is the composition of ERINIAS-CV?
Each tablet contains cefuroxime axetil equivalent to cefuroxime 500 mg with potassium clavulanate equivalent to clavulanic acid 125 mg.
Why can ERINIAS-CV be useful in an existing antibiotic portfolio?
It adds a cefuroxime-clavulanate option alongside ERINIAS 250 and ERINIAS 500. This keeps multiple cefuroxime presentations within one brand family.
Is monopoly distribution available for ERINIAS-CV?
Territory-based monopoly arrangements can be offered for approved and available locations. Final rights are defined in the commercial agreement.
Is there a franchise or renewal fee?
No. Eridanus Healthcare follows a zero franchise fee and zero renewal charge model.
Who can enquire about the ERINIAS-CV business opportunity?
Pharmaceutical distributors, stockists, wholesalers and experienced medical representatives can enquire.
What documents are required before starting business?
A valid Drug Licence and GST registration are required for applicable pharmaceutical trade transactions.
How quickly are orders processed?
Verified orders are normally processed within 24 hours. Actual dispatch and delivery depend on inventory, destination and logistics.
Related Cefuroxime Products
- Cefuroxime axetil 250 mg tablets – ERINIAS 250
- Cefuroxime axetil 500 mg tablets – ERINIAS 500
These products allow partners to present a wider cefuroxime range under the ERINIAS brand family.
Business Enquiries for ERINIAS-CV
ERINIAS-CV is available for selected territories through Eridanus Healthcare’s pharmaceutical distribution network.
Partners already active in antibiotics, general medicine or institutional supply can enquire about territory status and commercial terms.
Every enquiry is evaluated against territory availability and applicable trade documentation.
B2B Disclaimer
This page is intended for pharmaceutical distributors, wholesalers, and healthcare professionals. Product information is provided for commercial and educational reference and is not a substitute for professional medical advice. Eridanus Healthcare does not sell directly to patients. This is a Schedule H drug — to be sold by retail only on the prescription of a Registered Medical Practitioner. All trade enquiries are subject to valid Drug Licence and GST verification.